Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial
Identifieur interne : 001A46 ( PascalFrancis/Checkpoint ); précédent : 001A45; suivant : 001A47Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial
Auteurs : William G. Ondo [États-Unis] ; Yavuz S. Silay [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Flumazenil is a short-acting intravenously administered "7-aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different locations. We conducted a double-blind, placebo controlled, single dose, cross-over trial of flumazenil and placebo in 16 subjects with PD. Subjects were primarily assessed with serial tapping tests (1 minute for each hand) at 15-minute intervals for 90 minutes after infusion. Secondary assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) Motor part at baseline and 45 minutes after infusion, and global impressions. Subjects then underwent a 90-minute washout and entered the opposite arm of the cross-over. Change in tapping speed compared to baseline improved throughout the 90-minute period (P < 0.0001) and at each individual time (P < 0.01), except for 15 minutes status after infusion, with flumazenil compared to placebo. UPDRS scores tended to improve more on drug, but this finding was not significant. The medication was well tolerated. The most common adverse event on drug was a sense of "light-headedness" or "dizziness." GABA antagonists represent a novel potential treatment class for PD.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0538576Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Silay, Yavuz S" sort="Silay, Yavuz S" uniqKey="Silay Y" first="Yavuz S." last="Silay">Yavuz S. Silay</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Medicine, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0538576</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0538576 INIST</idno><idno type="RBID">Pascal:06-0538576</idno><idno type="wicri:Area/PascalFrancis/Corpus">001966</idno><idno type="wicri:Area/PascalFrancis/Curation">001355</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial</title><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Silay, Yavuz S" sort="Silay, Yavuz S" uniqKey="Silay Y" first="Yavuz S." last="Silay">Yavuz S. Silay</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Medicine, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benzodiazepine derivatives</term><term>Flumazenil</term><term>GABA</term><term>Intravenous administration</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Placebo</term><term>Single dose</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Voie intraveineuse</term><term>Flumazénil</term><term>Dose unique</term><term>Placebo</term><term>GABA</term><term>Benzodiazépine dérivé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Flumazenil is a short-acting intravenously administered "7-aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different locations. We conducted a double-blind, placebo controlled, single dose, cross-over trial of flumazenil and placebo in 16 subjects with PD. Subjects were primarily assessed with serial tapping tests (1 minute for each hand) at 15-minute intervals for 90 minutes after infusion. Secondary assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) Motor part at baseline and 45 minutes after infusion, and global impressions. Subjects then underwent a 90-minute washout and entered the opposite arm of the cross-over. Change in tapping speed compared to baseline improved throughout the 90-minute period (P < 0.0001) and at each individual time (P < 0.01), except for 15 minutes status after infusion, with flumazenil compared to placebo. UPDRS scores tended to improve more on drug, but this finding was not significant. The medication was well tolerated. The most common adverse event on drug was a sense of "light-headedness" or "dizziness." GABA antagonists represent a novel potential treatment class for PD.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>10</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial</s1></fA08><fA11 i1="01" i2="1"><s1>ONDO (William G.)</s1></fA11><fA11 i1="02" i2="1"><s1>SILAY (Yavuz S.)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medicine, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA20><s1>1614-1617</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000158877800060</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>29 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0538576</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Flumazenil is a short-acting intravenously administered "7-aminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different locations. We conducted a double-blind, placebo controlled, single dose, cross-over trial of flumazenil and placebo in 16 subjects with PD. Subjects were primarily assessed with serial tapping tests (1 minute for each hand) at 15-minute intervals for 90 minutes after infusion. Secondary assessments included the Unified Parkinson's Disease Rating Scale (UPDRS) Motor part at baseline and 45 minutes after infusion, and global impressions. Subjects then underwent a 90-minute washout and entered the opposite arm of the cross-over. Change in tapping speed compared to baseline improved throughout the 90-minute period (P < 0.0001) and at each individual time (P < 0.01), except for 15 minutes status after infusion, with flumazenil compared to placebo. UPDRS scores tended to improve more on drug, but this finding was not significant. The medication was well tolerated. The most common adverse event on drug was a sense of "light-headedness" or "dizziness." GABA antagonists represent a novel potential treatment class for PD.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B17A03</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Voie intraveineuse</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Intravenous administration</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Vía intravenosa</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Flumazénil</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Flumazenil</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Flumazenilo</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Dose unique</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Single dose</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Dosis única</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Placebo</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>GABA</s0><s2>NK</s2><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>GABA</s0><s2>NK</s2><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>GABA</s0><s2>NK</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Benzodiazépine dérivé</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Benzodiazepine derivatives</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Benzodiazepina derivado</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Neurotransmetteur</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Neurotransmitter</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Neurotransmisor</s0><s5>41</s5></fC07><fN21><s1>353</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name></region><name sortKey="Silay, Yavuz S" sort="Silay, Yavuz S" uniqKey="Silay Y" first="Yavuz S." last="Silay">Yavuz S. Silay</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 001A46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:06-0538576
|texte= Intravenous flumazenil for Parkinson's disease : A single dose, double blind, placebo controlled, cross-over trial
}}
| This area was generated with Dilib version V0.6.23. |  |